IRIS
DE LORENZO, CLAUDIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.137
NA - Nord America 4.785
EU - Europa 3.652
SA - Sud America 637
AF - Africa 151
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 14.367
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.591
SG - Singapore 2.129
RU - Federazione Russa 1.678
VN - Vietnam 1.069
CN - Cina 1.002
IT - Italia 706
BR - Brasile 496
HK - Hong Kong 394
DE - Germania 263
FR - Francia 176
FI - Finlandia 154
NL - Olanda 142
IE - Irlanda 111
JP - Giappone 107
CA - Canada 106
GB - Regno Unito 104
UA - Ucraina 100
IN - India 99
BD - Bangladesh 72
SE - Svezia 68
MX - Messico 52
CI - Costa d'Avorio 50
KR - Corea 48
AR - Argentina 47
PL - Polonia 44
ZA - Sudafrica 40
AT - Austria 28
EC - Ecuador 28
IQ - Iraq 28
PH - Filippine 28
ES - Italia 24
TH - Thailandia 20
TR - Turchia 20
ID - Indonesia 17
CO - Colombia 16
PK - Pakistan 15
TW - Taiwan 15
VE - Venezuela 13
PY - Paraguay 12
CL - Cile 10
LT - Lituania 9
MA - Marocco 9
UZ - Uzbekistan 9
BE - Belgio 8
CH - Svizzera 7
EG - Egitto 7
JM - Giamaica 7
JO - Giordania 7
TN - Tunisia 7
AE - Emirati Arabi Uniti 6
PE - Perù 6
CR - Costa Rica 5
IR - Iran 5
RS - Serbia 5
SA - Arabia Saudita 5
AL - Albania 4
AU - Australia 4
AZ - Azerbaigian 4
DZ - Algeria 4
ET - Etiopia 4
KZ - Kazakistan 4
LB - Libano 4
MY - Malesia 4
NP - Nepal 4
PA - Panama 4
RO - Romania 4
SN - Senegal 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
BO - Bolivia 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
HN - Honduras 3
IL - Israele 3
KE - Kenya 3
KW - Kuwait 3
LV - Lettonia 3
NG - Nigeria 3
OM - Oman 3
SY - Repubblica araba siriana 3
AO - Angola 2
BH - Bahrain 2
BZ - Belize 2
CG - Congo 2
GT - Guatemala 2
LA - Repubblica Popolare Democratica del Laos 2
LU - Lussemburgo 2
LY - Libia 2
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
BB - Barbados 1
BF - Burkina Faso 1
BG - Bulgaria 1
BM - Bermuda 1
BW - Botswana 1
BY - Bielorussia 1
DK - Danimarca 1
EU - Europa 1
GF - Guiana Francese 1
GM - Gambi 1
Totale 14.341
Salva come PNG Salva come JPEG
Città #
Singapore 987
San Jose 815
Chandler 427
Moscow 425
Hong Kong 385
Ashburn 360
Beijing 327
Ho Chi Minh City 318
Naples 243
Hanoi 200
Santa Clara 194
Los Angeles 147
The Dalles 147
Amsterdam 135
Hefei 121
Jacksonville 113
Lauterbourg 110
Millbury 96
Munich 93
Princeton 90
Tokyo 88
New York 87
Boston 85
Nanjing 64
Dallas 63
Napoli 62
Buffalo 61
São Paulo 55
Houston 54
Wilmington 47
Haiphong 45
Da Nang 44
Warsaw 39
Helsinki 38
Frankfurt am Main 36
Pune 32
Chicago 31
Woodbridge 31
Ottawa 29
Rome 29
Atlanta 28
Montreal 28
Orem 28
Seattle 28
Des Moines 27
Redondo Beach 27
London 26
Turku 26
Brooklyn 25
Cagliari 25
Council Bluffs 24
Seoul 24
Stockholm 23
Denver 22
Mexico City 22
Nanchang 22
Hải Dương 19
Rio de Janeiro 19
Shanghai 19
Falls Church 18
Falkenstein 17
Kronberg 17
Lawrence 17
Shenyang 17
Johannesburg 16
Biên Hòa 15
Boardman 15
Jiaxing 15
Phoenix 15
Poplar 15
San Francisco 15
Tianjin 15
Düsseldorf 14
Ercolano 14
Milan 14
Nuremberg 14
Quito 14
Toronto 14
Capaccio 13
Manchester 13
Washington 13
Chennai 12
Dong Ket 12
Kunming 12
Norwalk 12
Thái Bình 12
Vienna 12
Can Tho 11
Hebei 11
Perugia 11
Baghdad 10
Kochi 10
Ninh Bình 10
Acerra 9
Ankara 9
Changsha 9
Hyderabad 9
New Delhi 9
Campinas 8
Columbus 8
Totale 7.741
Salva come PNG Salva come JPEG
Nome #
A novel ErbB2 epitope targeted by Human antitumor Immunoagents 189
A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab 178
Oncolytic Adenoviral Vector-Mediated Expression of an Anti-PD-L1-scFv Improves Anti-Tumoral Efficacy in a Melanoma Mouse Model 176
Tri-specific tribodies targeting 5T4, CD3, and immune checkpoint drive stronger functional T-cell responses than combinations of antibody therapeutics 174
Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2 172
Ranolazine attenuates trastuzumab-induced heart dysfunction by modulating ROS production 170
Long-chain polyphosphates impair SARS-CoV-2 infection and replication 170
A novel fully human Antitumor ImmunoRNase targeting ErbB2-positive tumors 161
Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer 160
Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma 152
One-Step Recovery of scFv Clones from High-Throughput Sequencing-Based Screening of Phage Display Libraries Challenged to Cells Expressing Native Claudin-1 152
Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology 150
Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries 149
Immunotoxins and ImmunoRNases 147
Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells 147
Novel Human Anti-ErbB2 Immunoagents 146
Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies. 146
Novel Human Anti-ErbB2 Immunoagents 145
Effects of a human compact anti-ErbB2 antibody on prostate cancer 145
Novel human anti-Claudin 1 monoclonal antibodies inhibit HCV infection and may synergize with anti-SRB1 mAb. 145
A long non-coding SINEUP RNA boosts semi-stable production of fully human monoclonal antibodies in HEK293E cells 145
Antitumor pancreatic-type RNases 141
Nuovi agenti con attività antitumorale nei tumori ErbB2-positivi 140
Novel Human Bispecific Aptamer-Antibody Conjugates for Efficient Cancer Cell Killing 140
Mechanisms of cardiotoxicity associated with ErbB2 inhibitors. 138
Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling 138
Human Antitumor RNases and ImmunoRNases 136
Novel combinations of human immunomodulatory mAbs lacking cardiotoxic effects for therapy of TNBC 135
New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC 134
Anti-ErbB2 human Immunoagents 134
Effects of protein RNase inhibitor and substrate on the quaternary structures of bovine seminal RNase 134
Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. 134
Interactions of spike‐rbd of sars‐cov‐2 and platelet factor 4: New insights in the etiopathogenesis of thrombosis 134
High-Throughput Monoclonal Antibody Discovery from Phage Libraries: Challenging the Current Preclinical Pipeline to Keep the Pace with the Increasing mAb Demand 134
Evaluation of the antiproliferative effect of Bifidobacterium longum BB-536 in solid tumor cell lines, co-cultured with murine splenocytes 134
Esiste la possibilità di ipotizzare un blocco dei recettori HER con immunoagenti senza effetti cardiotossici? 133
The molecular basis for the production of an antitumor protein 133
Fusion protein comprising three binding domains to HER2 133
The singular case of seminal RNase, a dimer with two quaternary conformations, inspected with Trypsin as a conformational probe 130
Immunomodulatory mabs as tools to investigate on cis-interaction of pd-1/pd-l1 on tumor cells and to set up methods for early screening of safe and potent combinatorial treatments 130
Fusion proteins 128
Thermodynamic stability of the two isoforms of bovine seminal ribonuclease. 128
Anti-ErbB2 Human Immunoagents 128
The antitumor action of seminal ribonuclease and its quaternary conformations 128
Anti-ErbB2 immunoagents 127
Comparative Analysis of a Human Neutralizing mAb Specific for SARS-CoV-2 Spike-RBD with Cilgavimab and Tixagevimab for the Efficacy on the Omicron Variant in Neutralizing and Detection Assays 126
8th International Meeting on Ribonucleases 124
A novel fully human antitumor ImmunoRNase targeting ErbB2-positive tumors 124
T-cell Activating Tribodies as a Novel Approach for Efficient Killing of ErbB2-positive Cancer Cells. 124
Novel Bi-Specific Immuno-Modulatory Tribodies Potentiate T Cell Activation and Increase Anti-Tumor Efficacy 123
Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent. 123
Anti-ErbB2 human immunoagents 123
Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo 122
A Novel Human Anti-tumor Dimeric ImmunoRNase 121
Trypsin sheds light on the singular case of seminal RNase, a dimer with two quaternary conformations. 120
Bovine Seminal RNase: an atypical member of the ribonuclease superfamily 120
A novel ErbB2 epitope targeted by human antitumor immunoagents 119
A new human antitumor immunoreagent specific for ErbB2 119
First and Second Generation Human anti-ErbB2 Immunoagents 119
A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy 119
Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells. 119
RANOLAZINE AT THE END OF TRASTUZUMAB THERAPY PREVENTS LEFT VENTRICULAR DYSFUNCTION: IN VITRO AND IN VIVO STUDY 118
IMMUNORNASES AS ANTITUMOUR AGENTS 117
Human, Anti-ErbB2 Antitumor Immunoagents 117
A novel fully human antitumor ImmunoRNase resistant to the RNase inhibitor. 117
Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways 117
HUMAN ANTI-FV ANTIBODY, THERAPEUTIC AND DIAGNOSTIC APPLICATIONS THEREOF 116
Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells 116
Human anti-nucleolin recombinant immunoagent for cancer therapy 116
A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory Antibodies 114
A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours. 114
Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of Ranolazine 113
Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents 112
A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent 110
Differential binding of human immunoagents and Herceptin to the ErbB2 receptor 110
A study of the Intracellular Routing of Cytotoxic Ribonucleases 109
Effects of a human compact anti-ErbB2 antibody on gastric cancer. 109
Evidences of CTLA-4 and PD-1 blocking agents-induced cardiotoxicity in cellular and preclinical models 108
Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge 107
Dramatic potentiation of the antiviral activity of HIV antibodies by cholesterol conjugation. 107
Superior Suppression of ErbB2-positive Tumor Cells by a Novel Human Triparatopic Tribody 107
A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells. 106
Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin 106
Binding of human immunoagents and Herceptin to the ErbB2 receptor 105
Inhibition of cardiomyocytes late I-Na with ranolazine blunts anthracyclines-cardiotoxicity in experimental models in vitro and in vivo 105
Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2 104
A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas. 104
NOVEL HUMAN ANTI-ErbB2 IMMUNOAGENTS 104
ImmunoRNases as antitumor agents 103
Human mini-antibody cytotoxic for tumor cells which express the ErbB2 receptor 101
Novel human anti-ErbB2 immunoagents 101
Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction 101
Speckle tracking echocardiography identifies cardiac dysfuntion induced by the anticancer ErbB2-blocker Lapatinib. 101
Effects of three different anti-ErbB2 antibodies on prostate tumors 100
Methods and compositions relating to Anti-nucleolin recombinant immunoagents 100
DOXORUBICIN-INDUCED CARDIOTOXICITY IN MICE IS PREVENTED BY LATE INA INHIBITION WITH RANOLAZINE, WITH IMPROVEMENT IN HEART FUNCTION, FIBROSIS AND APOPTOSIS 99
The antineoplastic ErbB2-antibody 2c4 produces left ventricular dysfunction in murine hearts. 96
Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors 96
A Novel Human Anti-FV mAb as a Potential Tool for Diagnostic and Coagulation Inhibitory Approaches 94
Filamentous Phage Display 92
Totale 12.640
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.325
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.325
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022704 4 4 2 3 12 16 22 34 122 48 194 243
2022/20231.010 124 77 31 86 123 118 5 85 171 116 57 17
2023/2024724 27 112 128 47 30 92 22 107 1 17 91 50
2024/20253.701 158 143 37 50 120 242 357 212 223 420 1.440 299
2025/20267.268 786 506 686 647 1.290 288 929 376 863 555 185 157
2026/202790 90 0 0 0 0 0 0 0 0 0 0 0
Totale 14.555